EUFOREA consensus on biologics for CRSwNP with or without asthma

Forskningsoutput: TidskriftsbidragÖversiktsartikel


Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.


  • Wytske J. Fokkens
  • Valerie Lund
  • Claus Bachert
  • Joaquim Mullol
  • Jean Bousquet
  • Giorgio W. Canonica
  • Lauren Deneyer
  • Martin Desrosiers
  • Joseph Han
  • Enrico Heffler
  • Claire Hopkins
  • Roger Jankowski
  • Guy Joos
  • Andrew Knill
  • Jivianne Lee
  • Stella E. Lee
  • Gert Mariën
  • Benoit Pugin
  • Brent Senior
  • Sven F. Seys
  • Peter W. Hellings
Enheter & grupper
Externa organisationer
  • Academic Medical Center
  • Royal National Throat, Nose and Ear Hospital
  • Ghent University
  • Karolinska University Hospital
  • University of Barcelona
  • Arnaud de Villeneuve Hospital
  • Humanitas Clinical and Research Center
  • Humanitas University
  • Centre hospitalier de l'Université de Montréal
  • University Medical Center Groningen
  • Charles University in Prague
  • Eastern Virginia Medical School
  • Guy's and St Thomas' NHS Foundation Trust
  • Ghent University Hospital
  • University of California, Los Angeles
  • University of Pittsburgh
  • Catholic University of Leuven
  • University of North Carolina
  • University Hospitals Leuven
  • European Forum for Research and Education in Allergy and Airway diseases (EUFOREA)
  • University Hospital of Nancy
  • Opuscomms

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Lungmedicin och allergi


TidskriftAllergy: European Journal of Allergy and Clinical Immunology
StatusE-pub ahead of print - 2019
Peer review utfördJa